Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635

The distribution of 5-HT1A receptors was examined in the post-mortem human brain using whole hemisphere autoradiography and the selective 5-HT1A receptor antagonist [3H]WAY-100635 ([O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2- pyridinyl)cyclohexanecarboxamide trihydrochloride). The autoradiograms showed very dense binding to hippocampus, raphe nuclei and neocortex. The labeling in neocortex was slightly lower than in the hippocampus and was mainly at superficial layers, although a faintly labeled band could be seen in deeper neocortical layers. Other regions, such as the amygdala, septum and claustrum, showed low densities caudatus and putamen, in cerebellum or in structures of the brain stem except in the raphe nuclei. The labeling of human 5-HT1A receptors with [3H]WAY-100635 was antagonised by the addition of 5-HT1A receptor ligands, 5-HT, buspirone, pindolol or 8-OH-DPAT (10 microM), leaving a very low background of non-specific binding. Saturation analysis of semiquantitative data from several human regions indicated that [3H]WAY-100635 has a Kd of approximately 2.5 nM. The selective labeling of 5-HT1A receptors with [3H]WAY-100635 clearly show that this compound is useful for further studies of the human 5-HT1a receptor subtype in vitro [11C]WAY-100635 is used for the characterization of 5-HT1A receptors with positron emission tomography (PET). WAY-100635 was also radiolabeled with the short-lived positron-emitting radionuclide carbon-11 (t1/2 = 20 min) and used for in vitro autoradiography on human whole hemisphere cryosections. [11C]WAY-100635 gave images qualitatively similar to those of [3H]WAY-100635, although with a lower resolution. Thus, the hippocampal formation was densely labeled, with lower density in the neocortex. Buspirone, pindolol or 8-OH-DPAT (10 microM), blocked all binding of [11C]WAY-100635. The in vitro autoradiography of the distribution of 5-HT1A receptors obtained with radiolabeled WAY-100635 provide detailed qualitative and quantitative information on the distribution of 5-HT1A-receptors in the human brain. Moreover, the studies give reference information for the interpretation of previous initial results at much lower resolution in humans with PET and [11C]Way-100635. These data provide a strong basis for expecting [11C]WAY-100635 to behave as a highly selective radioligand in vivo.

[1]  F. Yocca Neurochemistry and Neurophysiology of Buspirone and Gepirone: Interactions at Presynaptic and Postsynaptic 5‐HT1A Receptors , 1990, Journal of clinical psychopharmacology.

[2]  D. Baldwin,et al.  The role of serotonin in depression and anxiety , 1995, International clinical psychopharmacology.

[3]  B. Långström,et al.  In vivo and in vitro receptor autoradiography of the human brain using an 11C-labelled benzodiazepine analogue , 1988, Neuroscience Letters.

[4]  G. Sedvall,et al.  Autoradiography with saturation experiments of 11C-Ro 15–1788 binding to human brain sections , 1991, Journal of Neuroscience Methods.

[5]  Anat Biegon,et al.  Autoradiographic analysis of serotonin 5-HT1A receptor binding in the human brain postmortem: effects of age and alcohol , 1991, Brain Research.

[6]  M. Minchin,et al.  Characterisation of the Binding of [3H]WAY‐100635, a Novel 5‐Hydroxytryptamine1A Receptor Antagonist, to Rat Brain , 1995, Journal of neurochemistry.

[7]  G. Wooten,et al.  Quantitative film autoradiography of opiate agonist and antagonist binding in rat brain. , 1983, The Journal of pharmacology and experimental therapeutics.

[8]  H. Wikström,et al.  Potential anxiolytic properties of R-(+)-8-OSO2CF3-PAT, a 5-HT 1A receptor agonist. , 1996, European journal of pharmacology.

[9]  A A Lammertsma,et al.  Evaluation of [O-methyl-3H]WAY-100635 as an in vivo radioligand for 5-HT1A receptors in rat brain. , 1994, European journal of pharmacology.

[10]  X. Khawaja,et al.  Quantitative autoradiographic characterisation of the binding of [3H]WAY-100635, a selective 5-HT1A receptor antagonist , 1995, Brain Research.

[11]  A. S. Eison,et al.  Buspirone: review of its pharmacology and current perspectives on its mechanism of action. , 1986, The American journal of medicine.

[12]  G. Sedvall,et al.  Carbon-11 labelling of eticlopride in two different positions--a selective high-affinity ligand for the study of dopamine D-2 receptors using PET. , 1990, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[13]  D. Wright,et al.  Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain , 1995, The Journal of comparative neurology.

[14]  P R Saxena,et al.  Serotonin receptors: subtypes, functional responses and therapeutic relevance. , 1995, Pharmacology & therapeutics.

[15]  J. Kleinman,et al.  Serotonin Uptake Sites and Serotonin Receptors Are Altered in the Limbic System of Schizophrenics , 1993, Neuropsychopharmacology.

[16]  S. Paul,et al.  Preclinical Pharmacology of Buspirone Hydrochloride , 1984, Pharmacotherapy.

[17]  L. Descarries,et al.  Serotonin 5-HT1 and 5-HT2 receptors in adult rat brain after neonatal destruction of nigrostriatal dopamine neurons: a quantitative autoradiographic study , 1993, Brain Research.

[18]  M. Hamon,et al.  Selective in vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse. , 1994, European journal of pharmacology.

[19]  J. Palacios,et al.  Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites , 1986, Brain Research.

[20]  Christer Halldin,et al.  Autoradiographic localization of extrastriatal D2‐dopamine receptors in the human brain using [125I]epidepride , 1996, Synapse.

[21]  Christer Halldin,et al.  Distribution of D1- and D2-Dopamine Receptors, and Dopamine and Its Metabolites in the Human Brain , 1994, Neuropsychopharmacology.

[22]  S. Hjorth,et al.  Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors? , 1986, European journal of pharmacology.

[23]  P. Grasby,et al.  Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. , 1996, Nuclear medicine and biology.

[24]  Allan Fletcher,et al.  Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist , 1995, Behavioural Brain Research.

[25]  M. Mintun,et al.  [11C]WAY 100635: a radioligand for imaging 5-HT1A receptors with positron emission tomography. , 1994, Life sciences.

[26]  S. Peroutka,et al.  Antagonism of 5-hydroxytryptamine1A (5-HT1A) receptor-mediated modulation of adenylate cyclase activity by pindolol and propranolol isomers. , 1988, Biochemical pharmacology.

[27]  Paul J. Harrison,et al.  The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain , 1995, Brain Research.

[28]  I. Martin,et al.  Molecular biology of 5-HT receptors , 1994, Neuropharmacology.

[29]  J. Palacios,et al.  Serotonin receptors in the human brain—IV. Autoradiographic mapping of serotonin-2 receptors , 1987, Neuroscience.

[30]  P A Sargent,et al.  Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. , 1996, European journal of pharmacology.

[31]  J. Glowinski,et al.  Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT , 1983, Nature.

[32]  I A Cliffe,et al.  A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. , 1995, European journal of pharmacology.

[33]  A Malizia,et al.  First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635. , 1995, European journal of pharmacology.

[34]  M. Hamon,et al.  The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes. , 1995, European journal of pharmacology.

[35]  S. Hjorth,et al.  8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. , 1981, Journal of medicinal chemistry.

[36]  C. Dourish,et al.  Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents. , 1993, Trends in pharmacological sciences.

[37]  M. Hamon,et al.  [3H]8‐Hydroxy‐2‐(Di‐n‐Propylamino)Tetralin Binding to Pre‐ and Postsynaptic 5‐Hydroxytryptamine Sites in Various Regions of the Rat Brain , 1985, Journal of neurochemistry.

[38]  L. Farde,et al.  Positron emission tomography--examination of chemical transmission in the living human brain. Development of radioligands. , 1992, Arzneimittel-Forschung.

[39]  H. Berendsen,et al.  Interactions between 5-hydroxytryptamine receptor subtypes: is a disturbed receptor balance contributing to the symptomatology of depression in humans? , 1995, Pharmacology & therapeutics.

[40]  H. Meltzer,et al.  Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia , 1996, Brain Research.

[41]  S. Watson,et al.  Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain — a combined in situ hybridisation/in vitro receptor autoradiographic study , 1991, Brain Research.